---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Pharmacology questions"
description: "Pharmacology questions on Enhertu (fam-trastuzumab deruxtecan-nxki) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Components, and Pharmacokinetics. Questions: How does Enhertu work (mechanism of action)? How many deruxtecan molecules are attached to each Enhertu antibody? What are the inactive ingredients in Enhertu? What is the half-life of Enhertu? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/enhertu/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Pharmacology questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)  
Indication pages: [HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)

## Mechanism

<a id="enhertu-mechanism"></a>

### How does Enhertu work (mechanism of action)?

> “Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate. 
> The antibody is a humanized anti-HER2 IgG1. The small molecule, DXd, is a 
> topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following 
> binding to HER2 on tumor cells, fam-trastuzumab deruxtecan-nxki undergoes 
> internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, 
> the membrane-permeable DXd causes DNA damage and apoptotic cell death.”

Source: [ENHERTU: Prescribing information, page 17, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=17)

> “Fam-trastuzumab deruxtecan-nxki is an antibody-drug 
> conjugate (ADC) composed of three components: 1) a humanized anti-HER2 IgG1 
> monoclonal antibody (mAb), covalently linked to 2) a topoisomerase I inhibitor, via 
> 3) a tetrapeptide-based cleavable linker. Deruxtecan is composed of a protease-
> cleavable maleimide tetrapeptide linker and the topoisomerase inhibitor, DXd, 
> which is an exatecan derivative.”

Source: [ENHERTU: Prescribing information, page 17, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=17)

<a id="enhertu-drug-antibody-ratio"></a>

### How many deruxtecan molecules are attached to each Enhertu antibody?

> “Approximately 8 molecules of deruxtecan are attached to each antibody 
> molecule.”

Source: [ENHERTU: Prescribing information, page 17, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=17)

## Components

<a id="enhertu-inactive-ingredients"></a>

### What are the inactive ingredients in Enhertu?

> “ENHERTU (fam-trastuzumab deruxtecan-nxki) is a sterile, white to yellowish 
> white, preservative-free lyophilized powder in single-dose vials. Each vial delivers 
> 100 mg of fam-trastuzumab deruxtecan-nxki, L-histidine (4.45 mg), L-histidine 
> hydrochloride monohydrate (20.2 mg), polysorbate 80 (1.5 mg), and sucrose 
> (450 mg). Following reconstitution with 5 mL of Sterile Water for Injection, USP, 
> the resulting concentration of fam-trastuzumab deruxtecan-nxki is 20 mg/mL 
> with a pH of 5.5. The resulting solution is administered by intravenous infusion 
> following dilution.”

Source: [ENHERTU: Prescribing information, page 17, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=17)

## Pharmacokinetics

<a id="enhertu-half-life"></a>

### What is the half-life of Enhertu?

> “The median elimination half-life of fam-trastuzumab deruxtecan-nxki is 5.4 to  
> 5.7 days. The estimated systemic clearance of fam-trastuzumab deruxtecan-nxki is 
> 0.4 L/day (24%).
> The median elimination half-life of DXd is 5.4-6.1 days. The estimated systemic 
> clearance of DXd is 18 L/h (28%).”

Source: [ENHERTU: Prescribing information, page 17, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=17)

> “Accumulation of 
> fam-trastuzumab deruxtecan-nxki is approximately 1.4-fold at steady-state (Cycle 3).”

Source: [ENHERTU: Prescribing information, page 17, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=17)

<a id="enhertu-metabolism"></a>

### How is Enhertu metabolized?

> “Metabolism
> The monoclonal antibody is expected to be degraded into small peptides and amino 
> acids via catabolic pathways.
> DXd is primarily metabolized by CYP3A4.”

Source: [ENHERTU: Prescribing information, page 17, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=17)

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): All indications](https://www.evicenter.com/medical-information/enhertu)
- [Indication](https://www.evicenter.com/medical-information/enhertu/indication)
- [Safety](https://www.evicenter.com/medical-information/enhertu/safety)
- [Specific populations](https://www.evicenter.com/medical-information/enhertu/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/enhertu/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/enhertu/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/enhertu/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/enhertu/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/enhertu/guidelines)
